Mosquito-borne Flavivirus Zika and Chikungunya Virus to Trigger Stroke, Study Suggests

Jan 12, 2021- by CMI| Category : Clinical Diagnostic1 min read
Mosquito-borne Flavivirus Zika and Chikungunya Virus to Trigger Stroke, Study Suggests

According to a new collaborative research study initiated by the researchers of University of Liverpool researchers and Brazilian collaborators have reported that combination of two lethal mosquito-borne viruses including Zika and chikungunya might act as a trigger for stroke. Moreover, Zika which is responsible for brain damage in babies following infection in pregnancy, however this new research reveals its potential to cause nervous system disease in adults.

This research included study of 201 adults with new onset neurological disease, who were treated in Brazil during the 2015-2016 Zika and chikungunya epidemics in the region. The new research reveals that each virus can cause numerous neurological problems. However, researchers observed that probability of stroke was high in patients who were infected with both the viruses together. Stroke occurs when there is blockage in one of the arteries that supplies blood to the brain.

Moreover, the average age of patients was 48, and around 50% of the total participants were female. Researchers also reported that the out of the stroke patients, of an average age of 67, around 2/3 were infected with both the viruses. This indicates that risk of stroke was high in following Zika and chikungunya viral infection in patients who were previously at higher risk for stroke.

Dr. Maria Lúcia Brito Ferreira, leading the Brazilian team stated, “Zika infection most often causes a syndrome of rash and fever without many long-term consequences, but these neurological complications—although rare—can require intensive care support in hospital, often result in disability, and may cause death.”

Researchers concluded that further studies are required for better understanding of the viruses and why some viruses trigger stroke, in order to develop novel drugs to prevent this health condition.

Share this story

About the author

Ravina Pandya

is a seasoned content writer with over 3.5 years of hands-on experience across various writing formats, including news articles, blog posts, press releases, and informational content. Her expertise lies in producing high-quality, informative content tailored to meet the specific needs of diverse industries, such as Biotechnology, Clinical Diagnostic, Healthcare IT, advanced material, and Medical Devices. She has a deep understanding of how to craft engaging narratives that align with industry trends, helping businesses enhance their online presence and communicate effectively with their audiences.

What sets Ravina apart is her keen eye for detail and her passion for storytelling. She approaches every piece of content with the intent to make it not just informative but also impactful, ensuring that it resonates with the audience on a deeper level. With a reputation for producing timely and relevant articles, she has made significant contributions to the field by helping companies effectively communicate their brand message through engaging, clear, and creative writing. As an advocate for clarity in communication, she continues to explore new ways of refining her craft while remaining at the forefront of content trends.